Wacker Biotech offers a series of proprietary bacterial E. coli strains that produce biologics for its customers.

The demand for nucleic acid-based gene therapies, novel vaccines, innovative therapeutic agents including messenger RNA (mRNA) and viral vectors is high. Plasmid DNA (pDNA) is the basis for all these advanced therapies. Wacker Biotech’s versatile plug-and-play platform PLASMITEC^® is based on decades of hands-on experience in pDNA manufacturing for both early stage and Phase III clinical trials.

They float in a murky soup of nutrients in huge steel tanks: life forms too small to be seen by the naked eye. These are bacterial strains, which grow and reproduce. Wacker Biotech uses them to produce drugs: so-called Live Biotherapeutic Products (LBPs). This is a promising class of therapeutic products. The purpose of these LBPs is to cure or prevent a wide variety of diseases, including cancer as well as infectious, inflammatory, metabolic and dermatological diseases.